FDA's GMP Expectations for Phase I and First-in-Man Clinical Trials

3962

Duration : 90 Minutes

Peggy J Berry,

Peggy J. Berry, MBA, RAC, is the President & CEO at Synergy Consulting where she provides consulting services to companies in all aspects of drug development. She also provides group and one-on-one training in drug development, regulatory affairs and project management topics. Prior to founding Synergy Consulting in 2015, Read more

Early clinical trials are conducted to establish initial safety of a drug. The studies are generally in small number of healthy subjects and use lower doses of the drug product. Therefore, only small amounts of investigational material are required. In order to not undertake substantial costs and to reduce regulatory burden during these early stages, the FDA has established guidelines to allow early stage investigational products to be manufactured under less stringent GMPs.

Course Objective:

To gain an understanding of the requirements for advancing drugs from research into early clinical development and the minimum FDA requirements for phase I GMPs. To learn practical applications for implementing phase I manufacturing strategies to meet FDA requirements. This webinar will provide the foundation and basis for advancing drugs into clinical development from research and providing required information to the FDA regarding these products. It will provide valuable guidance to provide the requirements for early stage products of different types and for vendor selection and management.

• Directors• Manager• Supervisors• Lead workers in Regulatory Affairs Quality Assurance and Quality Control• Workers who will prepare GMP documents for early phase products• Workers who will review GMP documents for early phase products• Regulatory affairs workers who will need to deal with submissions covering early phase products